Research study Program year 2019 Source: CMS Open Payments

DXPN 1807

Research payments

$269,990

15 payments

Through program year 2019, $269,990 in research payments was reported against DXPN 1807, across 15 payments, paid by Taro Pharmaceuticals USA, Inc..

Paid by: Taro Pharmaceuticals USA, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2019	Research	$269,990	15

Breakdown

Who paid Research payments · program year 2019

Taro Pharmaceuticals USA, Inc. $269,990 15 payments

Who received the money Research payments · program year 2019

Fxm Clinical Research Miami Llc Organisation paid for research $101,873 4 payments
Fxm Clinical Research Miramar LLC Organisation paid for research $65,255 4 payments
FXM Research Corp Organisation paid for research $41,850 2 payments
3A Research, LLC Organisation paid for research $35,965 2 payments
Moore Clinical Research, Inc. Organisation paid for research $21,898 2 payments
FXM International Organisation paid for research $3,150 1 payment

Usually the institution or organisation running the study, not a person.

What the money was spent on Research payments · program year 2019

Professional salary support $265,490 13 payments
Overhead $3,000 1 payment
Other $1,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

7 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.